Apigenin is often described as a phytoestrogen, and it does interact with estrogen receptors. So the first surprise in the polycystic ovary syndrome literature is the direction of the hormone results: across three separate rat studies, apigenin lowered estradiol. It also lowered testosterone, lowered the LH to FSH ratio, and raised progesterone. That is closer to what a PCOS patient would want than what the phytoestrogen label predicts, and it is a good illustration of why that label is too crude to be useful.
Key Takeaways
- In three rat models apigenin reduced ovarian cysts, restored follicular development and increased corpora lutea, alongside lower testosterone, lower estradiol, lower LH to FSH ratio and higher progesterone.
- One study ran metformin as a comparator and described the apigenin effect as parallel to it to some extent, which is a modest claim rather than equivalence.
- A 2025 study found the effect partly antiangiogenic, with reduced VEGF and VEGFR2 expression. That is framed as beneficial in PCOS, but VEGF suppression is not a neutral thing in an ovary.
- The three studies used three different induction methods: DHEA, estradiol valerate and bisphenol A. These do not model the same disease.
- The rat doses convert to roughly 220 to 450 mg for an adult human, far above typical capsule sizes. No human PCOS trial of apigenin exists.
The Hormone Results, and Why They Are Consistent
A 2020 study in Gynecological Endocrinology divided 32 female Wistar rats into control, PCOS control, and apigenin groups at 20 and 40 mg/kg for 21 days.[1] Serum estrogen and testosterone fell. Luteinizing hormone fell, and so did the LH to FSH ratio, while FSH itself rose. Progesterone rose. TNF-alpha, IL-6 and total oxidative status all dropped, while total antioxidant capacity and superoxide dismutase activity increased.
The ovarian histology matched the hormones. Cyst number fell. Theca layer thickness fell. Granulosa layer thickness increased and corpora lutea increased, which together suggest follicles progressing to ovulation rather than arresting.
A 2022 study in Annals of Medicine reproduced the pattern in a different model, using dehydroepiandrosterone to induce PCOS in Sprague Dawley rats with metformin as the standard comparator.[2] Apigenin improved lipid profile and antioxidant status, normalized body weight, reduced ovarian diameter and cysts, restored healthy follicles, suppressed estradiol and testosterone, raised progesterone, and reduced TNF-alpha and IL-6.
The comparator detail is the one worth holding onto. The authors write that the effects of apigenin were to some extent parallel to metformin. That phrasing is doing real work. It is not a claim of equivalence, and it comes from a 21-day rat study, not a head-to-head trial in women.
The reason the hormone direction is not actually contradictory is that apigenin has been reported to inhibit aromatase, the enzyme converting androgens to estrogens, while also binding estrogen receptors weakly. Those are opposing actions on the same axis, and which one dominates depends on the tissue and the baseline hormonal state. In a hyperandrogenic, cystic ovary the reported net effect was suppression of both estradiol and testosterone. Calling the compound a phytoestrogen flattens all of that.
The Antiangiogenic Finding, and the Tension In It
A 2025 study in Naunyn-Schmiedeberg Archives of Pharmacology used a different induction method again, a single injection of estradiol valerate, and dosed 28 rats with apigenin at 10 or 20 mg/kg for 14 days.[3]
Apigenin partially restored follicular development, decreased cyst number, increased corpora lutea and reduced ovarian collagen density. The mechanism the authors identify is vascular: apigenin reduced endothelial and periendothelial cell numbers and decreased expression of VEGF and its receptor VEGFR2, also called KDR.
Abnormal vascular growth is a documented feature of polycystic ovaries, so reducing it is a defensible therapeutic direction and the authors present it that way. It is worth noticing the other side. VEGF signaling is required for normal follicular development, corpus luteum formation and early pregnancy support. Ovarian angiogenesis is not simply a pathology to be suppressed, and a compound that lowers VEGF and VEGFR2 in an ovary is not obviously safe in a woman actively trying to conceive, which describes a large share of the PCOS population. No study has examined that question.
Three Models Are Not One Disease
The three rodent studies above used dehydroepiandrosterone, estradiol valerate and, in a fourth study, bisphenol A in zebrafish.[4] Each produces some features resembling PCOS, and each does so by a different route: androgen excess, estrogen disruption, and endocrine-disrupting chemical exposure respectively.
Human PCOS is a heterogeneous syndrome diagnosed on combinations of ovulatory dysfunction, hyperandrogenism and ovarian morphology, with insulin resistance common but not universal. Consistency across three animal models is genuinely encouraging, because an effect that survives three different induction methods is less likely to be an artifact of one of them. It is not the same as evidence in the syndrome as it presents in women, and none of these models reproduces the metabolic phenotype that drives much of the long-term risk.
The zebrafish study is worth reading with the most caution of the four. Its experimental design was informed by computational docking against the human androgen receptor, and its endpoints are antioxidant enzyme activities, histology, tissue bisphenol A accumulation and gene expression. It is a toxicology model of a pollutant exposure, useful for mechanism and several steps removed from a clinical claim.
A 2024 review in Biomedicines surveys apigenin across female reproductive function and reaches a similar position, describing potential across folliculogenesis, hormone release, ovarian blood supply and several pathologies including PCOS and endometriosis, framed throughout as potential rather than established.[5]
The Doses Do Not Match a Capsule
Converting animal doses to human equivalents using the standard body surface area method, rats scale down by roughly a factor of six. The 20 to 40 mg/kg range used in the two hormone studies converts to roughly 3.2 to 6.5 mg/kg in a human, which is about 225 to 455 mg for a 70 kg adult. The 10 to 20 mg/kg range in the angiogenesis study converts to roughly 110 to 225 mg.
Typical apigenin capsules supply 25 mg or 50 mg. The rat findings sit several times above that, and taking more is not a straightforward fix, because absorption rather than dose is the binding constraint. Human pharmacokinetic work found free apigenin poorly absorbed, with urinary metabolite recovery equivalent to roughly 0.5 percent of intake, and circulating apigenin present mostly as glucuronide and sulfate conjugates rather than the free compound.[6] Glycoside forms from food were absorbed far better, which is a formulation observation rather than a dosing instruction.
How This Differs From the Phytoestrogen Question
Apigenin and estrogen receptor activity is a separate topic, concerned with receptor binding, aromatase and what those mean across the menstrual cycle and menopause. That literature asks how the compound behaves on the estrogen axis in general.
PCOS research asks whether a specific ovarian pathology improves: cysts, anovulation, hyperandrogenism, the LH to FSH ratio. The results here happen to run opposite to the naive phytoestrogen prediction, which is the clearest evidence that these are different questions and one does not answer the other.
The Practical Position
PCOS is a condition where the treatable consequences are the ones that matter most: insulin resistance progressing toward type 2 diabetes, unopposed estrogen exposure raising endometrial cancer risk over years of anovulation, and infertility with time-sensitive treatment windows. Established management addresses each of those. None of them has been shown to respond to apigenin in a person.
Several specific interactions belong in a conversation with a clinician rather than a self-directed trial. Letrozole, widely used for ovulation induction in PCOS, is an aromatase inhibitor, and apigenin has reported aromatase-inhibiting activity, so the combination is a pharmacodynamic overlap nobody has characterized. Combined oral contraceptives are metabolized by cytochrome P450 enzymes that apigenin inhibits, which is a concern when contraceptive efficacy is the point. Metformin, spironolactone and clomiphene all warrant the same caution for the same reason. And for anyone actively pursuing pregnancy, the VEGF suppression finding and the general caution around apigenin in pregnancy both apply.
Bottom Line
The PCOS evidence is unusually consistent for preclinical work: three rodent models with three different induction methods all showed fewer ovarian cysts, restored follicular development, more corpora lutea, lower testosterone and estradiol, lower LH to FSH ratio, higher progesterone and reduced inflammatory cytokines. One study ran metformin alongside and called the effect parallel to some extent. The mechanism includes an antiangiogenic component with reduced VEGF and VEGFR2, which is presented as beneficial and is not unambiguously so in an ovary. The doses convert to several hundred milligrams in a human, absorption of free apigenin is around half a percent, and no woman with PCOS has been studied taking it.
Frequently Asked Questions
Does apigenin help PCOS?
In rat models of PCOS apigenin reduced ovarian cysts, restored follicular development, increased corpora lutea, lowered testosterone and estradiol, lowered the LH to FSH ratio, raised progesterone and reduced TNF-alpha and IL-6. All of this is preclinical. No human trial of apigenin in PCOS has been conducted.
Does apigenin raise or lower estrogen in PCOS?
In the PCOS rat studies apigenin lowered estradiol, despite apigenin often being described as a phytoestrogen. Apigenin both binds estrogen receptors weakly and inhibits aromatase, and in a hyperandrogenic cystic ovary the reported net effect was suppression of both estradiol and testosterone.
Is apigenin safe to take with PCOS medication?
This has not been studied and there are specific reasons for caution. Letrozole used for ovulation induction is an aromatase inhibitor and apigenin has reported aromatase-inhibiting activity, an uncharacterized overlap. Combined oral contraceptives are metabolized by cytochrome P450 enzymes that apigenin inhibits. A 2025 study also found apigenin reduced ovarian VEGF and VEGFR2 expression, which is relevant for anyone trying to conceive.
References
- Darabi P, Khazali H, Mehrabani Natanzi M. Therapeutic potentials of the natural plant flavonoid apigenin in polycystic ovary syndrome in rat model: via modulation of pro-inflammatory cytokines and antioxidant activity. Gynecological Endocrinology (2020). PMID 31888395
- Peng F, Hu Y, Peng S, Zeng N, Shi L. Apigenin exerts protective effect and restores ovarian function in dehydroepiandrosterone induced polycystic ovary syndrome rats: a biochemical and histological analysis. Annals of Medicine (2022). PMID 35152800
- Samani SL, Yadi M, Aflatoonian B, et al. Beneficial effects of apigenin on ovarian histological changes and angiogenesis gene expression in rat model of polycystic ovary syndrome. Naunyn-Schmiedeberg Archives of Pharmacology (2025). PMID 39240354
- Sudhakaran G, Gopi S, Priya S, et al. Apigenin regulates bisphenol-A induced polycystic ovarian syndrome symptoms in-vivo zebrafish. Reproductive Sciences (2025). PMID 40148704
- Sirotkin AV, Harrath AH. Apigenin as a promising agent for enhancing female reproductive function and treating associated disorders. Biomedicines (2024). PMID 39457717
- Borges G, Fong RY, Ensunsa JL, et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radical Biology and Medicine (2022). PMID 35452808
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
